PMID- 32212153
OWN - NLM
STAT- MEDLINE
DCOM- 20210402
LR  - 20210402
IS  - 1097-0215 (Electronic)
IS  - 0020-7136 (Linking)
VI  - 147
IP  - 5
DP  - 2020 Sep 1
TI  - Multiple low-frequency and rare HLA-B allelic variants are associated with 
      reduced risk in 1,105 nasopharyngeal carcinoma patients in Hunan province, 
      southern China.
PG  - 1397-1404
LID - 10.1002/ijc.32992 [doi]
AB  - In our study, 1,105 cases of nasopharyngeal carcinoma (NPC) and 1,430 normal 
      controls recruited from Hunan province, southern China were typed for human 
      leukocyte antigen (HLA)-B locus by Sanger sequencing exons 2-4. Besides 
      confirming the NPC association with HLA-B*46:01 allele, HLA-A*02:07-B*46:01 and 
      HLA-A*33:03-B*58:01 haplotypes (all positive), and HLA-B*13 lineage (negative), 
      all of which were relatively common, strong negative associations were observed 
      for five low-frequency and rare alleles or lineages, including HLA-B*07, 
      -B*27:04, -B*39, -B*51:02 and -B*55:02, with odds ratio (OR) ranging from 0.16 to 
      0.3 (all p(corrected) < 0.05). These strong protective associations were 
      independent of linkage disequilibrium (LD) between HLA-A and HLA-B loci. Further 
      analysis indicated a single amino acid change from histidine to tyrosine at 
      residue 171 is probably crucial for the mutant allele, HLA-B*51:02, to mediate 
      resistance to NPC. A subset of NPC cases (n = 821) and normal controls (n 
      = 1,035) were tested for antivirus capsid antigen immunoglobulin A (anti-VCA 
      IgA), which differed drastically between the two groups [67.7% vs. 5.5%, OR (95% 
      confidence interval) = 36 (26.55-48.81), p < 0.0001]. HLA-B allelic variation did 
      not associate with seropositivity for anti-VCA IgA in either group. Results from 
      our study show, more clearly than previously, the existence of a cluster of 
      low-frequency and rare HLA-B variants conferring low, or very low risk to NPC, a 
      phenomenon not observed in other ethnic groups. Our data shed new insights into 
      genetic susceptibility to NPC in southern Chinese populations. Future independent 
      studies are warranted to replicate the findings reported in our study.
CI  - (c) 2020 UICC.
FAU - Tian, Wei
AU  - Tian W
AUID- ORCID: 0000-0002-8109-9924
AD  - Immunogenetics Research Group, Department of Immunology, College of Basic Medical 
      Sciences, Central South University, Changsha, Hunan, China.
AD  - Laboratory of Cellular and Molecular Biology, College of Basic Medical Sciences, 
      Central South University, Changsha, Hunan, China.
FAU - Zhu, FaMing
AU  - Zhu F
AD  - HLA typing laboratory, Blood Center of Zhejiang Province, Hangzhou, Zhejiang, 
      China.
AD  - Key Laboratory of Blood Safety Research, Zhejiang Province, Hangzhou, Zhejiang, 
      China.
FAU - Cai, JinHong
AU  - Cai J
AD  - Immunogenetics Research Group, Department of Immunology, College of Basic Medical 
      Sciences, Central South University, Changsha, Hunan, China.
FAU - Li, LiXin
AU  - Li L
AD  - Laboratory of Cellular and Molecular Biology, College of Basic Medical Sciences, 
      Central South University, Changsha, Hunan, China.
FAU - Jin, HeKun
AU  - Jin H
AD  - Department of Radiotherapy, Hunan Cancer Hospital (the affiliated Cancer Hospital 
      of XiangYa School of Medicine of Central South University), Changsha, Hunan, 
      China.
FAU - Wang, WenYi
AU  - Wang W
AD  - Immunogenetics Research Group, Department of Immunology, College of Basic Medical 
      Sciences, Central South University, Changsha, Hunan, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200409
PL  - United States
TA  - Int J Cancer
JT  - International journal of cancer
JID - 0042124
RN  - 0 (HLA-A Antigens)
RN  - 0 (HLA-B Antigens)
SB  - IM
MH  - Adult
MH  - Alleles
MH  - China/epidemiology
MH  - Female
MH  - Gene Frequency
MH  - Genetic Predisposition to Disease/*genetics
MH  - HLA-A Antigens/genetics
MH  - HLA-B Antigens/*genetics
MH  - Haplotypes
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Mutation
MH  - Nasopharyngeal Carcinoma/epidemiology/*genetics
MH  - Nasopharyngeal Neoplasms/epidemiology/*genetics
MH  - Odds Ratio
OTO - NOTNLM
OT  - HLA-B
OT  - nasopharyngeal carcinoma
OT  - rare allele
OT  - sequencing
OT  - southern Chinese population
EDAT- 2020/03/27 06:00
MHDA- 2021/04/07 06:00
CRDT- 2020/03/27 06:00
PHST- 2019/12/04 00:00 [received]
PHST- 2020/03/05 00:00 [revised]
PHST- 2020/03/10 00:00 [accepted]
PHST- 2020/03/27 06:00 [pubmed]
PHST- 2021/04/07 06:00 [medline]
PHST- 2020/03/27 06:00 [entrez]
AID - 10.1002/ijc.32992 [doi]
PST - ppublish
SO  - Int J Cancer. 2020 Sep 1;147(5):1397-1404. doi: 10.1002/ijc.32992. Epub 2020 Apr 
      9.